Refludan

Company
Hoechst Marion Roussel

Approval Status
Approved March 1998

Treatment for
heparin-induced thrombocytopenia type II

Areas
Hematology

Refludan has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT type II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood's platelet count, leading to an increased risk of severe thromboembolic complications.

Refludan Drug Information

The Refludan drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top